

UNITED THERAPEUTICS CORP

Form 8-K

May 13, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15 (d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 13, 2003

United Therapeutics Corporation

---

(Exact Name of Registrant as Specified in Charter)

Delaware

---

(State or Other  
Jurisdiction of  
Incorporation)

000-26301

---

(Commission  
File Number)

52-1984749

---

(I.R.S. Employer  
Identification Number)

1110 Spring Street  
Silver Spring, MD

---

(Address of Principal Executive Offices)

20910

---

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

---

**Item 5. Other Events.**

On May 13, 2003, United Therapeutics Corporation (the Company) issued a press release, a copy of which is attached as Exhibit 99.1, announcing that Roger Jeffs, Ph.D., its President and Chief Operating Officer, has adopted a prearranged trading plan in accordance with Securities and Exchange Commission Rule 10b5-1.

**Item 7. Exhibits**

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated May 13, 2003

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: May 13, 2003

By: /s/ Paul A. Mahon

---

Name: Paul A. Mahon

Title: SVP and General Counsel

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated May 13, 2003